Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
      Google Scholar   
Citation:
J Clin Oncol vol 23 (10) 2191-200
Year:
2005
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
CA02599, CA03927, CA04326, CA04457, CA04919, CA07968, CA08025, CA11789, CA12046, CA12449, CA14028, CA16450, CA21060, CA26806, CA31809, CA31946, CA31983, CA32291, CA33601, CA35119, CA35178, CA35192, CA35279, CA37981, CA41287, CA42777, CA45377, CA45807, CA46113, CA46136, CA47559, CA47577, CA47642, CA58415, CA58416, CA58686, CA60138, CA63844, CA76447, CA76462, CA77202, CA77440, CA77651  
Corr. Author:
 
Authors:
                           
Networks:
 
Study
CALGB-9082
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Carmustine, Chemotherapy, Adjuvant, Cisplatin, Cyclophosphamide, Disease-Free Survival, Dose-Response Relationship, Drug, Female, Granulocyte Colony-Stimulating Factor, Humans, Lymphatic Metastasis, Middle Aged, Neoplasm Staging, Peripheral Blood Stem Cell Transplantation, Prognosis, Prospective Studies, Risk Factors, Treatment Outcome